🔥 biotech 핫 테마 분석

[AQST] Aquestive targets Q3 NDA resubmission for Anaphylm while maintaining 2026 revenue guidance of $46M-$50M

[BBIO] Canaccord raises BridgeBio Pharma stock price target on revenue beat

[SLN] Morgan Stanley maintains Overweight rating on Silence Therapeutics

S-Class [FENC] Fennec Pharmaceuticals GAAP EPS of $0.05 beats by $0.04, revenue of $17.87M beats by $1.75M

[LLY] Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.

Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.

[LLY] Eli Lilly’s weight-loss pill gets first European approval in U.K.

[BBIO] BridgeBio outlines three launches with first PDUFA set for November 27, 2026 and RECLAIM-HP readout in next 18 months